KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Operating Leases (2019 - 2025)

Pacira BioSciences (PCRX) has 7 years of Operating Leases data on record, last reported at $36.2 million in Q4 2025.

  • For Q4 2025, Operating Leases fell 18.97% year-over-year to $36.2 million; the TTM value through Dec 2025 reached $36.2 million, down 18.97%, while the annual FY2025 figure was $36.2 million, 18.97% down from the prior year.
  • Operating Leases reached $36.2 million in Q4 2025 per PCRX's latest filing, down from $38.8 million in the prior quarter.
  • Across five years, Operating Leases topped out at $77.7 million in Q1 2022 and bottomed at $36.2 million in Q4 2025.
  • Average Operating Leases over 5 years is $59.8 million, with a median of $61.2 million recorded in 2023.
  • Peak YoY movement for Operating Leases: skyrocketed 87.04% in 2021, then decreased 27.15% in 2024.
  • A 5-year view of Operating Leases shows it stood at $71.7 million in 2021, then decreased by 9.65% to $64.8 million in 2022, then fell by 15.43% to $54.8 million in 2023, then decreased by 18.54% to $44.6 million in 2024, then fell by 18.97% to $36.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $36.2 million in Q4 2025, $38.8 million in Q3 2025, and $50.9 million in Q2 2025.